Astellas Pharma Unsp/Adr (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 206,164 | 165,000 | 995,000 | 1,286,000 | 1,309,000 |
| Depreciation Amortization | 1,314,271 | 1,045,000 | 795,000 | 653,000 | 655,000 |
| Accounts receivable | -691,251 | -371,000 | -36,000 | -66,000 | 200,000 |
| Accounts payable and accrued liabilities | -75,299 | 195,000 | -92,000 | -83,000 | -465,000 |
| Other Working Capital | -1,662,190 | -826,000 | -703,000 | -297,000 | -447,000 |
| Other Operating Activity | 2,192,084 | 934,000 | 1,505,000 | 617,000 | 1,512,000 |
| Operating Cash Flow | $1,283,779 | $1,142,000 | $2,464,000 | $2,110,000 | $2,764,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -244,220 | -179,000 | -274,000 | -248,000 | -221,000 |
| Net Acquisitions | N/A | -5,199,000 | N/A | -5,000 | -134,000 |
| Sale Of Investment | 85,272 | N/A | 95,000 | N/A | N/A |
| Purchase Sale Intangibles | -126,509 | -294,000 | -390,000 | -176,000 | -415,000 |
| Other Investing Activity | -431,218 | -223,000 | -456,000 | -259,000 | -383,000 |
| Investing Cash Flow | $-590,165 | $-5,601,000 | $-635,000 | $-512,000 | $-738,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -1,560,563 | 2,148,000 | N/A | N/A | N/A |
| Debt Issued | 1,320,000 | 3,128,000 | 263,000 | -246,000 | -1,135,000 |
| Debt Repayment | -343,682 | -168,000 | -376,000 | -246,000 | N/A |
| Common Stock Repurchased | -45,936 | -71,000 | -455,000 | -416,000 | -83,000 |
| Dividend Paid | -851,354 | -773,000 | -755,000 | -699,000 | -686,000 |
| Other Financing Activity | -243,487 | -197,000 | -148,000 | -166,000 | -163,000 |
| Financing Cash Flow | $-1,725,022 | $4,067,000 | $-1,471,000 | $-1,773,000 | $-2,067,000 |
| Exchange Rate Effect | 59,136 | 120,000 | 99,000 | 91,000 | 111,000 |
| Beginning Cash Position | 2,215,534 | 2,496,000 | 2,376,000 | 2,673,000 | 2,868,000 |
| End Cash Position | 1,243,255 | 2,223,000 | 2,833,000 | 2,590,000 | 2,938,000 |
| Net Cash Flow | $-972,279 | $-273,000 | $457,000 | $-83,000 | $70,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,283,779 | 1,142,000 | 2,464,000 | 2,110,000 | 2,764,000 |
| Capital Expenditure | -244,220 | -252,000 | -274,000 | -252,000 | -283,000 |
| Free Cash Flow | 1,039,559 | 890,000 | 2,190,000 | 1,858,000 | 2,481,000 |